Deoxynivalenol impairs the immune functions of neutrophils
Date
2013Author
Gauthier, T
Wachأ©, Y
Laffitte, J
Taranu, I
Saeedikouzehkonani, N
Mori, Y
Oswald, IP
Metadata
Show full item recordAbstract
Scope: Deoxynivalenol (DON), a mycotoxin produced by Fusarium spp., is toxic to many animal species, with pigs being the most sensitive species to the toxin. The aim of the present study was to determine the effects of DON on pig polymorphonuclear cells (PMNs), the first line of defense against infection. Methods and results: PMNs isolated from pig blood samples were stimulated with LPS to mimic infection. DON (0.5-10 ?M) altered three main functions of pig PMNs: LPS-induced secretion of IL-8, chemotaxis, and phagocytosis capability. This alteration of PMN properties was due to apoptotis induced by DON exposure. Using Western blot and flow cytometry, we demonstrated that this process included the permeabilization of the mitochondrial outer membrane and the activation of caspase-3. The effect of DON was mediated by the phosphorylation of the p38 mitogen-activated protein kinase within the first 30 min of exposure. Conclusion: This study provides evidence that low concentrations of DON can alter the immune functions of porcine PMNs and suggests the involvement of p38 mitogen-activated protein kinase in the signal transduction pathway. These immunosuppressive effects of DON may have implications for humans and/or animals when eating contaminated food/feed. آ© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Collections
Related items
Showing items related by title, author, creator and subject.
-
A phase III, randomized, two-armed, double-blind, parallel, active controlled, and non-inferiority clinical trial to compare efficacy and safety of biosimilar adalimumab (CinnoRAآ®) to the reference product (Humiraآ®) in patients with active rheumatoid arthritis
Jamshidi, A; Gharibdoost, F; Vojdanian, M; Soroosh, SG; Soroush, M; Ahmadzadeh, A; Nazarinia, MA; Mousavi, M; Karimzadeh, H; Shakibi, MR; Rezaieyazdi, Z; Sahebari, M; Hajiabbasi, A; Ebrahimi, AA; Mahjourian, N; Rashti, AM (2017)Background: This study aimed to compare efficacy and safety of test-adalimumab (CinnoRAآ®, CinnaGen, Iran) to the innovator product (Humiraآ®, AbbVie, USA) in adult patients with active rheumatoid arthritis (RA). Methods: ... -
Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran.
Golestani, M; Eshghi, P; Rasekh, HR; Cheraghali, AM; Salamzadeh, J; Naderi, M; Managhchi, MR; Hoorfar, H; Toogeh, GR; Imani, A; Khodayari, MT; Habibpanah, B; Hantooshzadeh, R (2016)Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® ... -
Developmental minocycline treatment reverses the effects of neonatal immune activation on anxiety- and depression-like behaviors, hippocampal inflammation, and HPA axis activity in adult mice.
Majidi, J; Kosari-Nasab, M; Salari, AA (2016)Neonatal infection is associated with increased lifetime risk for neuropsychiatric disorders including anxiety and depression, with evidence showing that dysregulation of the hypothalamic-pituitary-adrenal-(HPA)-axis system ...